Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

OpenAI’s Quarterly Revenue Tops $10 Billion for the First Time, Up Nearly 50% in a Quarter, as Anthropic’s Growth Slows to About 47%

by Team Lumida
4 hours ago

OpenAI’s third-quarter revenue hit $10 billion for the first time, up nearly 50% from the prior quarter, as Anthropic’s growth slowed, Bloomberg reports.

Read more

FDA Orders Vision-Loss Warnings on Every GLP-1 Drug After Trials Show NAION Rates of 6.4 vs. 3.8 per 100,000 Patient-Years

by Team Lumida
20 hours ago
Bernie Sanders Pushes for Cheaper Wegovy: Can Novo Nordisk Resist?

The FDA will require all GLP-1 drugs, including Wegovy and Zepbound, to warn of a rare optic nerve condition that can cause sudden, permanent vision loss.

Read more

Anthropic Sets Its IPO Range at $70 to $78 for 825 Million Shares, Targeting a Nov. 19 Nasdaq Debut at Up to $1.405 Trillion

by Team Lumida
20 hours ago

Anthropic will sell 825 million shares at $70 to $78, raising up to $64.35 billion, and plans to price Nov. 18 and begin trading on Nasdaq Nov. 19.

Read more

Anthropic’s Retracted Prospectus Flashed 867 Million Shares at $70 to $80 Each, a $69.3 Billion Raise, as the Claude Maker Readies IPO Marketing in a Nervous AI Market

by Team Lumida
1 day ago

A leaked, retracted Anthropic filing pointed to a $69.3 billion raise at $70 to $80 a share, just as the Claude maker prepares to market its IPO.

Read more

AI Data Center Builders Face a 2027 Rate Shock, as $13.4 Billion of Maturing Debt Could Cost at Least $380 Million More to Refinance

by Team Lumida
2 days ago

BloombergNEF says refinancing 2027 data center debt at current Treasury yields would lift rates 2.85 points, with $1 trillion due in five years.

Read more

CoreWeave Bonds Yield Above 16% and Its Default Swaps Top 1,240 Basis Points Ahead of Tuesday’s Earnings as Neocloud Credit Fears Mount

by Team Lumida
2 days ago
How CoreWeave’s Nvidia Partnership is Disrupting Cloud Computing Giants

CoreWeave and Nebius have lost about half their value in a month, and some CoreWeave bonds yield over 16% ahead of Tuesday’s results.

Read more

Lilly’s Foundayo Pill Cuts Sleep Apnea Severity by 43.8% in a Late-Stage Trial, Setting Up an FDA Filing by Year-End

by Team Lumida
2 days ago

Eli Lilly’s Foundayo pill cut sleep apnea events by 21.1 an hour vs. 4.8 on placebo, and Lilly plans to seek U.S. approval by year-end.

Read more

Google Readies Two Specialized AI Chips as Bloomberg Intelligence Sees TPU Sales Topping $135 Billion by 2028, Adding Pressure on Nvidia

by Team Lumida
2 days ago
Google DeepMind Spinout Emulate Nears $4B Valuation After One Month; World Models Threaten $4.8T Gaming Industry

Google plans two specialized TPUs next year; Bloomberg Intelligence says they cost about 30% less than Nvidia GPUs and could top $135 billion in sales by 2028.

Read more

Trump Backs Nvidia’s Jensen Huang as a “Fine Person” Who Should Stay CEO After His Admitted Affair With a Suspected China Spy

by Team Lumida
2 days ago

Trump called Jensen Huang a “fine person” who should stay on as Nvidia CEO and said he is open to bringing him on an Asia trip later this...

Read more

SpaceX Proposes a $24 Billion Texas AI Supercomputer With Its Own 748-Megawatt Gas Plant, About 17 Times Its Bitcoin Holdings

by Team Lumida
2 days ago
SpaceXAI Plans a Unified Grok and X Subscription Spanning $8 to $100 a Month, Bundling AI With Checkmarks and Fewer Ads

SpaceX plans a $24 billion supercomputer and gas-fired power plant at Starbase, Texas, and is seeking a property tax break ahead of a Dec. 9 hearing.

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Disney Goes All-In on OpenAI, Turning Iconic IP Into an AI Video Platform

Disney Goes All-In on OpenAI, Turning Iconic IP Into an AI Video Platform

December 12, 2025
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

JPMorgan’s AI Investing Agents Beat the 60/40 Portfolio in 20-Year Backtests — With Lower Volatility

July 10, 2026
white and black concrete building

Nike, Adidas Urge Trump to Exempt Footwear From Tariffs, Citing Industry Risks

May 3, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018